Latest Financial Results
Q2 2019
Quarterly Results
Ended Apr 30, 2019
Stock Information
Symbol
ANIXPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.
Latest News & Events
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
Read More...Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived Suppressor Cells
Read More...Anixa Biosciences to Present at the CYTO 2019 - 34th Congress of the International Society for Advancement of Cytometry
Read More...Cancer Fact: Approximately 40 million mammograms are conducted annually.